SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Clausen Jonas)
 

Sökning: WFRF:(Clausen Jonas) > Improved outcome af...

  • Abrahamsson, Jonas,1954Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences (författare)

Improved outcome after relapse in children with acute myeloid leukaemia.

  • Artikel/kapitelEngelska2007

Förlag, utgivningsår, omfång ...

  • Wiley,2007

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/197190
  • https://gup.ub.gu.se/publication/197190URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-7067URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1945853URI
  • https://doi.org/10.1111/j.1365-2141.2006.06419.xDOI
  • https://lup.lub.lu.se/record/679528URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • In the Nordic Society for Paediatric Haematology and Oncology paediatric study acute myeloid leukaemia (AML) 93, event-free survival was 50% and overall survival was 66%, indicating that many patients were cured following relapse. Factors influencing outcome in children with relapsed AML were investigated. The study included all 146 children in the Nordic countries diagnosed with AML between 1988 and 2003, who relapsed. Data on disease characteristics and relapse treatment were related to outcome. Sixty-six percentage achieved remission with survival after relapse (5 years) 34 +/- 4%. Of 122 patients who received re-induction therapy, 77% entered remission with 40 +/- 5% survival. Remission rates were similar for different re-induction regimens but fludarabine, cytarabine, granulocyte colony-stimulating factor-based therapy had low treatment-related mortality. Prognostic factors for survival were duration of first complete remission (CR1) and stem cell transplantation (SCT) in CR1. In early relapse (<1 year in CR1), survival was 21 +/- 5% compared with 48 +/- 6% in late relapse. For children receiving re-induction therapy, survival in early relapse was 29 +/- 6% and 51 +/- 6% in late. Patients treated in CR1 with SCT, autologous SCT or chemotherapy had a survival of 18 +/- 9, 5 +/- 5 and 41 +/- 5%, respectively. Survival was 62 +/- 6% in 64 children given SCT as part of their relapse therapy. A significant proportion of children with relapsed AML can be cured, even those with early relapse. Children who receive re-induction therapy, enter remission and proceed to SCT can achieve a cure rate of 60%.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Clausen, Niels (författare)
  • Gustafsson, GöranKarolinska Institutet (författare)
  • Hovi, Liisa (författare)
  • Jonmundsson, Gudmundur (författare)
  • Zeller, Bernward (författare)
  • Forestier, ErikUmeå universitet,Pediatrik (författare)
  • Heldrup, JesperLund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)pedi-jhe (författare)
  • Hasle, Henrik (författare)
  • Göteborgs universitetInstitutionen för kliniska vetenskaper (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:British journal of haematology: Wiley136:2, s. 229-2360007-10481365-2141

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy